Farallon Capital Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-102,400
| Closed | -$5.41M | – | 152 |
|
|
2024
Q3 | $5.41M | Hold |
102,400
| – | – | 0.02% | 89 |
|
|
2024
Q2 | $5.55M | Hold |
102,400
| – | – | 0.02% | 85 |
|
|
2024
Q1 | $7.18M | Sell |
102,400
-985,372
| -91% | -$69.1M | 0.03% | 94 |
|
|
2023
Q4 | $90.8M | Buy |
1,087,772
+1,066,000
| +4,896% | +$89M | 0.42% | 47 |
|
|
2023
Q3 | $641K | Hold |
21,772
| – | – | ﹤0.01% | 114 |
|
|
2023
Q2 | $710K | Sell |
21,772
-916,300
| -98% | -$29.9M | ﹤0.01% | 125 |
|
|
2023
Q1 | $33M | Sell |
938,072
-763,666
| -45% | -$26.9M | 0.18% | 69 |
|
|
2022
Q4 | $78M | Buy |
1,701,738
+80,700
| +5% | +$3.7M | 0.46% | 52 |
|
|
2022
Q3 | $78.5M | Sell |
1,621,038
-624,000
| -28% | -$30.2M | 0.43% | 60 |
|
|
2022
Q2 | $88.2M | Buy |
2,245,038
+362,439
| +19% | +$14.2M | 0.48% | 57 |
|
|
2022
Q1 | $69.3M | Sell |
1,882,599
-287,743
| -13% | -$10.6M | 0.33% | 61 |
|
|
2021
Q4 | $98.9M | Sell |
2,170,342
-562,433
| -21% | -$25.6M | 0.49% | 47 |
|
|
2021
Q3 | $97.7M | Sell |
2,732,775
-143,225
| -5% | -$5.12M | 0.46% | 53 |
|
|
2021
Q2 | $56.9M | Buy |
2,876,000
+376,000
| +15% | +$7.44M | 0.23% | 66 |
|
|
2021
Q1 | $58.2M | Buy |
2,500,000
+100,000
| +4% | +$2.33M | 0.29% | 65 |
|
|
2020
Q4 | $49.9M | Buy |
2,400,000
+250,000
| +12% | +$5.2M | 0.3% | 62 |
|
|
2020
Q3 | $46.5M | Buy |
2,150,000
+650,000
| +43% | +$14.1M | 0.32% | 65 |
|
|
2020
Q2 | $35.4M | Buy |
1,500,000
+875,000
| +140% | +$20.6M | 0.28% | 66 |
|
|
2020
Q1 | $7.37M | Buy |
+625,000
| New | +$7.37M | 0.06% | 84 |
|